Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis 35624
- Development stage
- Phase 3
- Lead developer
- Procter & Gamble
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis 35624 is a well-characterized probiotic bacterial strain originally isolated from the healthy human gut and widely studied for its effects on digestive health, particularly irritable bowel syndrome (IBS). Genomic sequencing has led to its reclassification as *Bifidobacterium longum* subsp. *longum* 35634, but it remains best known and marketed as *Bifidobacterium infantis* or *Bifantis*. This live biotherapeutic product is administered orally and has demonstrated safety and survivability through the gastrointestinal tract, reaching the gut alive[1][5]. Clinical studies have shown that supplementation with this strain can reduce symptoms of IBS such as abdominal pain/discomfort, bloating/distention, and difficulty passing stool[1][8][9]. The mechanism of action includes modulation of immune responses—specifically normalizing cytokine profiles such as IL-10/IL-12—and supporting a balanced gut microbiome[1][5]. It is included in international clinical guidelines for IBS management due to its evidence base[5].
- Brand names
- BifantisAlignPrecisionBiotics
- Other names
- bifidobacterium longum subsp. longum 35634
Beyond the preview
Go deeper on bifidobacterium infantis 35624.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis 35624.